Atorvastatin Calcium Hydrate/Sitagliptin Phosphate Monohydrate

阿托伐他汀钙/磷酸西格列汀一水合物

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAtorvastatin Calcium Hydrate/Sitagliptin Phosphate Monohydrate

Drug Alias NameSitagliptin Phosphate Monohydrate/Atorvastatin Calcium Hydrate磷酸西格列汀一水合物/阿托伐他汀钙Atorvastatin/Sitagliptinsitagliptin/atorvastatinMK-0431E

ClassificationSmall molecules

Mechanisms of ActionHMG-CoA reductase inhibitorsDipeptidyl peptidase IV inhibitors

TargetsDipeptidyl peptidase IVHMG-CoA reductase

Therapy Area/IndicationsDiabetes MellitusAtherosclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Sitagliptin Phosphate Monohydrate Atorvastatin Calcium Hydrate

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMerck & Co Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMerck Sharp & Dohme Corp

Active IndicationsN/A

Inactive IndicationsDiabetes MellitusAtherosclerosis

Other Information

ATC CodeN/A